熊去氧胆酸治疗胃癌术后胆汁反流性残胃炎患者的疗效  

Therapeutic Effect of Ursodeoxycholic Acid on Postoperative Bile Reflux Residual Gastritis in Patients with Gastric Cancer

作　　者：朱晓峰 ZHU Xiao-Feng(Gastroenterology Department,the First Affiliated Hospital of University of Science and Technology of China,Gastroenterology,University of Science and Technology of China,Gastroenterology\Hefei 230031,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)消化内科,合肥230031

出　　处：《中国药物经济学》2021年第1期49-52,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨熊去氧胆酸联合枸橼酸莫沙必利及铝碳酸镁对胃癌术后胆汁反流性残胃炎患者的治疗效果。方法选取2017年5月至2019年4月中国科学技术大学附属第一医院收治的胃癌术后胆汁反流性残胃炎患者52例作为研究对象,按照随机数字表法分为对照组和观察组,每组26例。对照组患者给予铝碳酸镁咀嚼片联合枸橼酸莫沙必利片治疗,观察组患者在对照组治疗基础上口服熊去氧胆酸胶囊治疗。比较两组患者治疗前后临床症状积分、临床疗效及用药安全性。结果治疗4周后,两组患者症状积分下降,与治疗前比较,差异有统计学意义(P<0.05);治疗4周后,观察组腹痛、腹胀、恶心、呕吐临床症状积分与对照组比较,差异无统计学意义(P>0.05),但两组嗳气临床症状积分比较,差异有统计学意义(P<0.05)。对照组治疗有效率为69.23%,观察组治疗有效率为92.31%,观察组患者临床治疗有效率高于对照组,差异有统计学意义(P<0.05)。两组患者未发生严重不良反应,且临床症状较轻,差异无统计学意义(P>0.05)。结论在枸橼酸莫沙必利与铝碳酸镁治疗方案的基础上联合熊去氧胆酸,治疗胆汁反流性残胃炎,能够提高治疗疗效,快速缓解临床症状,安全性较高。Objective To investigate the therapeutic effect of ursodeoxycholic acid combined with mosapride and magnesium aluminum carbonate on postoperative bile reflux gastritis in patients with gastric cancer.Methods From May 2017 to April 2019,a total of 52 patients with gastric cancer who underwent Bi-type II(gastric jejunal anastomosis)in the First Affiliated Hospital of USTC were selected as the research objects and were randomly divided into a control group and an observation group,with 26 patients in each group.Patients in the control group were given magnesium aluminocarbonate combined with mosapride tablets.Patients in the observation group took ursodeoxycholic acid capsule plus magnesium aluminocarbonate and mosapride tablets.The clinical symptom scores,clinical efficacy,and medication safety before and after treatment were compared between the 2 groups.Results After 4 weeks of treatment,the symptom scores of the 2 groups decreased.Compared with that before treatment,the difference was statistically significant(P<0.05).After 4 weeks of treatment,there was no significant difference in clinical symptom scores of abdominal pain,abdominal distension,nausea and vomiting between the observation group and the control group(P>0.05),but for the clinical symptom score of belching(P<0.05),there was significant difference between the 2 groups.The effective rate of the control group was 69.23%,and the effective rate of the observation group was 92.31%.The total effective rate of the clinical treatment in the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).No serious adverse reactions occurred in the 2 groups,and the clinical symptoms were mild,and the difference was not statistically significant(P>0.05).Conclusion Based on the treatment plan of mosapride and magnesium aluminum carbonate,combined with ursodeoxycholic acid,treatment of bile reflux residual gastritis can improve the therapeutic effect,quickly relieve clinical symptoms,and can be safe and reliab

关 键 词：熊去氧胆酸 胃癌术后 胆汁反流性 残胃炎 

分 类 号：R656.6[医药卫生—外科学] R982[医药卫生—药品]